Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. (2017)

• Record Type: Journal Article
• Authors: Iijima, Yuki; Hirotsu, Yosuke; Amemiya, Kenji; Higashi, Seishi; Miyashita, Yoshihiro; Omata, Masao
• Is Part Of: Respiratory medicine case reports. Volume 22(2017)
• Page Start: 31
• Page End: 33
• Publication Date: 2017
• Subjects: Circulating tumor DNA -- Immune checkpoint therapy -- Nivolumab -- Lung cancer -- PD-1; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2017.05.015
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: A 77-year-old Japanese man presented to our hospital with a 1-month history of low back pain and was diagnosed as having stage IV EGFR mutation-positive lung adenocarcinoma. After treatment with EGFR tyrosine kinase inhibitor and cytotoxic chemotherapy, nivolumab was started as fourth-line therapy. Remarkable regression of the primary tumor was observed, suggesting high anti-tumor activity of nivolumab. We retrospectively investigated the change in circulating tumor DNA (ctDNA) variant allele fractions in serial plasma samples before and after the nivolumab therapy. Targeted sequencing analysis showed tumor-derived TP53 R249S and EGFR L858R mutations detectable in plasma, and the timing of decrease was only 5 days, much earlier than the appearance of radiological changes. Overall, these results suggest that ctDNA might reflect tumor burden and might be a surrogate marker of the therapeutic efficacy of immune checkpoint therapy.